|
|
|
 |
FDA Approval Activities for this Drug…
VIRAMUNE (nevirapine) Tablets and Suspension, Boehringer Ingleheim NDA 20-636/S20 & 20-933/S10 7/29/03 8/6/03 8/6/03 | VIRAMUNE (nevirapine) Tablets and Suspension, Boehringer Ingleheim NDA 20-636/S-016 & 20-933/S-006 12/31/02 1/29/03 4/3/03 | Viramune (Nevirapine) Tablets & Solution, Boehringer Ingelheim NDA 20-636/S17 & 20-933/S7 | VIRAMUNE (nevirapine) Suspension, Boehringer Ingleheim Pharmaceuticals | VIRAMUNE (nevirapine) Tablets, Boehringer Ingleheim Pharmaceuticals | Lamivudine/Zidovudine Tablets co-packaged w/Nevirapine Tablets, Pharmacare Limited, Tentative Approval | Viramune (nevirapine) tablets, Boehringer Ingelheim Pharma, Labeling Revision | Viramune (nevirapine) oral suspension, Boehringer Ingelheim Pharma, Labeling Revision | Nevirapine Tablets, Aurobindo Pharma, Tentative Approval | Nevirapine Tablets, Ranbaxy, Tentative Approval | Nevirapine Tablets, Cipla Ltd., Tentative Approval | Nevirapine Tablets, Strides Acrolab, Tentative Approval | Lamivudine, Stavudine, Nevirapine Tablets, Cipla Ltd., Tentative Approval | Lamivudine/Zidovudine/Nevirapine Tablets, Aurobindo Pharma, Approval | Lamivudine/Zidovudine/Nevirapine Tablets, Cipla Ltd., Tentative Approval | Viramune (nevirapine) Tablets, Boehringer Ingelheim, Labeling Revision | Viramune (nevirapine) Oral Suspension, Boehringer Ingelheim, Labeling Revision | Nevirapine Tablets, Huahai Inc., Tentative Approval | Viramune (nevirapine) Tablets, Boehringer Ingelheim, Labeling Revision | Viramune (nevirapine) Oral Suspension, Boehringer Ingelheim, Labeling Revision | Lamivudine/Stavudine/Nevirapine Dispersible Tablets, Cipla Ltd., Tentative Approval | Nevirapine Tablets, Hetero Drugs, Tentative Approval | Nevirapine Tablets, Emcure Pharma, Tentative Approval | Stavudine/Lamivudine/Nevirapine Tablets, Strides Arcolab, Tentative Approval | Nevirapine Tablets, Matrix Laboratories, Ltd., Tentative Approval | Viramune (nevirapine) Oral Suspension, Boehringer Ingelheim Pharmaceuticals, Inc., Patient Population Altered | Viramune (nevirapine) Tablet, Boehringer Ingelheim Pharmaceuticals, Inc., Patient Population Altered | Stavudine, Lamivudine and Nevirapine Tablets, Pharmacare Ltd., Tentative Approval | Nevirapine Tablets, MacLeods Pharmaceuticals, Ltd., Tentative Approval | Stavudine, Lamivudine, and Nevirapine Tablets, Emcure Pharmaceuticals, Ltd., Tentative Approval | Viramune (nevirapine) Oral Suspension, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Viramune (nevirapine) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Lamivudine, Nevirapine, and Stavudine Tablets, Macleods Pharmaceuticals Ltd., Tentative Approval | Viramune (nevirapine) Oral Suspension, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Viramune (nevirapine) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Viramune XR (nevirapine) Extended-Release Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Approval | Viramune (nevirapine) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Viramune (nevirapine) Oral Suspension, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Viramune XR (nevirapine) Extended-Release Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Lamivudine, Tenofovir Disoproxil Fumarate and Nevirapine Tablets, Matrix Laboratories, Ltd., Tentative Approval | Viramune (nevirapine) Oral Suspension, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Viramune (nevirapine) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Viramune XR (nevirapine) Extended-Release Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Lamivudine, Nevirapine, and Zidovudine Tablets, Hetero Labs Limited Unit III, Tentative Approval
  
|